- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CTI adds CAD to PET/CT
Computer-aided detection, initially restricted to mammography, is entering the functional imaging arena. CTI Molecular Imaging is showcasing CAD technology during the RSNA meeting on its Reveal PET/CT scanners, as well as the Reveal MVS PET/CT workstation. Under a recently inked exclusive agreement with R2 Technology, CTI has begun offering the first commercially available CAD system for multidetector CT examinations of the chest.
Computer-aided detection, initially restricted to mammography, is entering the functional imaging arena. CTI Molecular Imaging is showcasing CAD technology during the RSNA meeting on its Reveal PET/CT scanners, as well as the Reveal MVS PET/CT workstation. Under a recently inked exclusive agreement with R2 Technology, CTI has begun offering the first commercially available CAD system for multidetector CT examinations of the chest.
The Reveal PET/CT system merges PET and CT technologies to generate functional and anatomical data in a single scan, which improves the localization of metabolic hot spots for cancer staging.
FDG, the active metabolite of PET scanning, accumulates not only in disease sites, but also in areas of inflammation and infection. The addition of CAD to the Reveal PET/CT system helps decipher inflammatory isotope uptake from metabolic localization of true malignant pathology so infection or inflammation in the pleural lining will not be mistaken for lung cancer.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
